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Using human blood samples obtained from pre-pandemic donors,
a recent article by Mateus et al. in Science provided new evidence
that SARS-CoV-2-reactive T-cells in unexposed donors are indeed
HCoV-specific T-cells.1
The rapid global spread of coronavirus disease 2019 (COVID-19),
caused by the newly-emerged coronavirus SARS-CoV-2, has led to
millions of infections with substantial morbidity and mortality.2
Different clinical manifestations of COVID-19 have been observed:
asymptomatic infections, mild self-limiting disease, acute respira-
tory distress syndrome and death. The determinants underlying
disease severity currently remain elusive; since severe patients
often present with immune hyperresponsiveness, it is speculated
that the host’ immune response could be a contributing factor to
severe disease.
Many studies are dissecting the human immune response to
SARS-CoV-2 and several groups have reported marked activation
of T-cell subsets in acute COVID-19 patients.3 The antigen-specific
T-cell response has only been analyzed in a handful of papers, all
sharing a common feature: although SARS-CoV-2-specific CD4+
and CD8+ T-cells are consistently detected in peripheral blood
mononuclear cells (PBMC) obtained from COVID-19 patients,
studies also report activation of T-cells in 20–50% of the people
never exposed to SARS-CoV-2.1,4,5 The frequency of these cross-
reactive responses in pre-pandemic controls is always low. On
average 1% of the CD4+ T-cells from acute COVID-19 patients
upregulate activation markers upon peptide pool stimulation. If
pre-pandemic donors respond to peptide stimulation, the
percentage of responding CD4+ T-cells is always <0.1%.5 Authors
of these papers speculate that these–mainly CD4+–SARS-CoV-2-
reactive T-cells are probably induced by past infection with one of
the endemic “common cold” coronaviruses (HCoVs), which share
at least partial sequence homology with SARS-CoV-2. Experimental
evidence for this hypothesis was lacking so far.
In this recent article in Science, the authors provided new
evidence that SARS-CoV-2-reactive T-cells in unexposed donors
are indeed HCoV-specific T-cells.1 The authors relied on an elegant
design of peptide “megapools” (MPs) to determine T-cell
specificities. Using these peptide pools in combination with
human PBMC obtained from donors between 2015 and 2018, the
authors identified 142 HLA class II-restricted SARS-CoV-2 T-cell
epitopes. Generation of several short-term T-cell lines proved that
at least a number of these T-cells recognized peptides derived
from HCoVs.
This research group previously developed the MP approach to
characterize T-cell responses targeting many different viruses in
vaccine recipients and convalescent donors (including SARS-CoV-2),
allowing them to simultaneously test large numbers of epitopes
even when sample size is limited.4,5 In this study, the authors
initially expanded PBMC from pre-pandemic donors by stimula-
tion with two different MPs: MP_CD4_S (containing predicted
epitopes of the S protein) and MP_CD4_R (containing predicted
epitopes of all other proteins). After expansion, T-cell reactivity to
smaller pools was determined, followed by reactivity to individual
peptides, a process known as deconvolution. This led to the
identification of 142 novel SARS-CoV-2 epitopes. Most frequent
and most vigorous responses were observed with antigens from
the S protein, although the mapped epitopes were distributed
fairly even over the proteome in proportion to protein size. In
addition to S, responses to ORF6, ORF3A, N, ORF8 and within
ORF1a (nsp3, nsp12, nsp4, nsp6, nsp2, and nsp14) were
prominently present. Antigen-specific cells responding to peptide
pool stimulation were mainly CD4+ T-cells. This was not surprising,
as the MPs employed contained long peptides (15 amino acids) of
predicted class II epitopes.
Although the experimental approach employed by the authors
(2-week expansion after direct peptide stimulation) allows for de
novo generation of responses from naive T-cells, they recognized
that the reactivity observed might reflect the presence of memory
T-cells cross-reactive between HCoVs and SARS-CoV-2. To study
this, the authors split the peptides used in these studies into 3
groups: (1) not immunogenic, (2) immunogenic in 1 donor, and (3)
immunogenic in multiple donors. In this analysis, they found that
peptides immunogenic in multiple donors indeed shared a higher
degree of amino acid homology between circulating HCoVs and
SARS-CoV-2.
Focusing on cross-reactive responses the authors now gener-
ated new MPs. For these cross-reactive MPs they selected all
epitopes with >67% amino acid homology and the highest
responders. In this way, they made a MP containing 31 “cross-
reactive” S epitopes (MP_CD4_S31) and a MP containing 30
“cross-reactive” epitopes spanning the rest of the proteome
(MP_CD4_R30). Simultaneously, they generated two other MPs
containing the homologous epitopes derived from different
HCoVs. They named these the MP_CD4_S124 and MP_CD4_R129
(containing 124 and 129 epitopes, respectively). These four MPs
were tested in two different cohorts, unexposed donors and
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COVID-19 convalescent donors. In these experiments, both
cohorts respond equally well to the HCoV MPs. The unexposed
cohort still responded to the SARS-CoV-2 pool, but not in the
magnitude observed in COVID-19 convalescent donors. These
data are consistent with the hypothesis that cross-reactive CD4+
T-cells between SARS-CoV-2 and other HCoVs exist in many
individuals.
For the final experiments, the authors generated 42 short-term
T-cell lines by stimulating PBMC with epitopes from the cross-
reactive SARS-CoV-2 MPs (S31 and R30). After generation of T-cell
lines, these were stimulated with a dilution series of the
recognized peptides obtained from either SARS-CoV-2 or the
other HCoVs. Ten out of 42 T-cell lines were identified as cross-
reactive. Similar experiments were performed with purified
memory and naïve T-cells, to prove that cross-reactive responses
in unexposed donors are derived from memory cells and were not
generated de novo.
The presence of T-cell-based cross-reactive immune memory in
unexposed donors had been reported by several studies, but the
basis for this memory remained speculative.4,5 This is the first
study that provides direct evidence that cross-reactive T-cell
responses could be induced by infection with any of the
circulating HCoVs: OC43, 229E, HKU1 or NL63.1
Virus-specific responses of the immune system are often termed
“immunity.” Although Mateus et al. clearly show the presence of
cross-reactive T-cell immunity to SARS-CoV-2 in unexposed
donors, it is important that this terminology is not misinterpreted
as “protective immunity.” The pre-existing cross-reactive immunity
(or better: immune memory) may impact COVID-19 disease
heterogeneity in different ways. At the moment it is unclear
whether this is a positive or negative contribution, pre-existing
cross-reactive T-cells could either ameliorate or worsen COVID-19
(Fig. 1). Clinical studies to answer this question are not easy, but
future prospective studies in which PBMC samples pre- and post-
COVID-19 are obtained from human donors are required. The
study by Mateus et al. makes clear that understanding the role of
T-cells in COVID-19 disease severity is crucial to inform vaccine
design and evaluation.
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Fig. 1 Pre-existing cross-reactive T-cell immunity could impact COVID-19 disease severity. Mateus et al. show the presence of pre-existing
T-cell immunity in pre-pandemic donors (donor a–d), induced by one or multiple of the seasonal HCoVs (left part of figure). It is still unclear
how pre-existing immunity impacts disease severity (or outcome) after SARS-CoV-2 exposure (right part of the figure). Different pre-exposure
history could lead to different cross-reactive T-cell responses and different disease severity
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